Vicis Clinical Research — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$1,265	2
2024	Research	$104,812	2
2023	Research	$101,842	5
2022	Research	$159,498	4

Breakdown

Who paid Research payments · program years 2022–2025

Eli Lilly and Company $201,780 7 payments
Otsuka Pharmaceutical Development & Commercialization, Inc. $164,371 4 payments
Ionis Pharmaceuticals, Inc. $1,265 2 payments

Studies the money was for Research payments · program years 2022–2025

A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease $175,372 4 payments
A Phase 3, 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Fixed-Dose Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (Opc-34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimers Type $74,235 1 payment
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Avp-786 (Deudextromethorphan Hydrobromide [D6-Dm]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimers Type $72,715 1 payment
A Donanemab (Ly3002813) Prevention Study in Participants With Alzheimer's Disease (Trailblazer-Alz 3) $26,409 3 payments
A 12-Week, Multicenter, Active-Treatment Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type $17,420 2 payments
Is354cs5 $1,265 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.